Curative Biotechnology（CUBT）株式概要開発段階のバイオメディカル企業であるキュラティブ・バイオテクノロジー社は、医薬品および医療機器の開発、ライセンス供与、商業化を行なっている。 詳細CUBT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間30%増加しました。 リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きいマイナスの株主資本 収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $11M )すべてのリスクチェックを見るCUBT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.61該当なし内在価値ディスカウントEst. Revenue$PastFuture-22m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesCurative Biotechnology, Inc. 競合他社CEL-SCISymbol: NYSEAM:CVMMarket cap: US$22.4mPsyence BiomedicalSymbol: NasdaqCM:PBMMarket cap: US$9.0mMoleculin BiotechSymbol: NasdaqCM:MBRXMarket cap: US$12.5mAprea TherapeuticsSymbol: NasdaqCM:APREMarket cap: US$9.6m価格と性能株価の高値、安値、推移の概要Curative Biotechnology過去の株価現在の株価US$1.6152週高値US$2.2352週安値US$0.031ベータ1.161ヶ月の変化46.36%3ヶ月変化51.60%1年変化-25.05%3年間の変化-23.33%5年間の変化-88.82%IPOからの変化-99.90%最新ニュースお知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605最新情報をもっと見るRecent updatesお知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605お知らせ • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.お知らせ • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.お知らせ • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unitお知らせ • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.お知らせ • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.お知らせ • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.お知らせ • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.お知らせ • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.株主還元CUBTUS BiotechsUS 市場7D9.7%-3.0%-0.3%1Y-25.0%32.9%26.7%株主還元を見る業界別リターン: CUBT過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: CUBTは、過去 1 年間で23.3 % のリターンを上げたUS市場を下回りました。価格変動Is CUBT's price volatile compared to industry and market?CUBT volatilityCUBT Average Weekly Movement29.5%Biotechs Industry Average Movement10.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: CUBTの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CUBTの weekly volatility ( 30% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995n/aI. Garrcurativebiotech.com開発段階のバイオメディカル企業であるキュラティブ・バイオテクノロジー社は、医薬品および医療機器の開発、ライセンス供与、商業化を行う。同社は、感染症、腫瘍、変性眼疾患などの治療分野に焦点を当てたパイプラインを開発している。同社のパイプライン候補には、中等度ドライ黄斑変性症や地理的萎縮症を治療するメトホルミン再製剤、後期狂犬病を治療する新規免疫治療薬IMT504、腫瘍の成長と移動を阻害することで腫瘍を死滅させるピロロベンゾジアゼピン二量体を腫瘍部位に直接運ぶ完全ヒト化CD56モノクローナル抗体CUBT906などがある。同社はMid-Atlantic BioTherapeutics, Inc.と、後期狂犬病治療薬IMT504およびCOVID-19ワクチンの開発に関するライセンス契約および共同開発契約を結んでいる。キュラティブ・バイオテクノロジー社はフロリダ州パームビーチガーデンズに本社を置いている。もっと見るCurative Biotechnology, Inc. 基礎のまとめCurative Biotechnology の収益と売上を時価総額と比較するとどうか。CUBT 基礎統計学時価総額US$11.44m収益（TTM）-US$2.84m売上高(TTM)n/a0.0xP/Sレシオ-4.1xPER（株価収益率CUBT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CUBT 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$2.84m収益-US$2.84m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.40グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-59.2%CUBT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 03:38終値2026/05/20 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curative Biotechnology, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000
お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42
お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6
お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605
お知らせ • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000
お知らせ • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42
お知らせ • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
お知らせ • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6
お知らせ • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605
お知らせ • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
お知らせ • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.
お知らせ • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unit
お知らせ • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.
お知らせ • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.
お知らせ • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
お知らせ • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.
お知らせ • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.
